DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor...
Plus, news about Palatin, Spero and BioAtla: DBV Technologies’ $306M financing: The French biotech could get up to that amount to help advance its peanut allergy patch for children through an ...
View ArticleMilestone's shares dive after FDA again rejects drug for abnormal heart rhythm
Milestone Pharmaceuticals’ nasal spray failed for a second time to secure US approval to treat an arrhythmia disorder called paroxysmal supraventricular tachycardia. The FDA’s complete response letter...
View ArticleCHMP acts on Opdivo, Tevimbra, Xoanacyl, Kisunla and others
Bristol Myers Squibb, BeiGene, AstraZeneca and Pfizer secured European backing for label expansions, and a French pharma got its first drug approval recommendation, in a list of actions by the European...
View ArticleJ&J wins patent feud against Viatris over schizophrenia drug
Johnson & Johnson scored an appeals court win in its bid to block generic competition for its long-acting schizophrenia drug. The US Court of Appeals for the Federal Circuit on Friday
View ArticleFDA approves Sanofi's RNAi drug for hemophilia A and B
The FDA on Friday said it approved a new RNAi-based hemophilia treatment from Sanofi that the company licensed from Alnylam. Patients with hemophilia A or B will now be able to ...
View ArticleNovartis’ radiopharma drug Pluvicto gets an expanded label
Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication. The FDA on Friday approved the drug for certain patients before they have...
View ArticleAmgen loses challenge to Colorado drug review board
A federal judge on Friday dismissed Amgen’s lawsuit against Colorado's drug affordability board and its call for a price cap on the company's blockbuster autoimmune drug. District Judge Nina Wang...
View ArticleBluebird gets new M&A bid, seeking to top private equity offer
A rival group is seeking to buy cell therapy biotech bluebird bio, in an effort to outbid a private equity offer by Carlyle and SK Capital, the company confirmed on Friday afternoon. The rival buying ...
View ArticleLykos’ interim CEO is set to step down
Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision. Mullette relayed the move to staff in February, saying that he would stay on...
View ArticleCOVID research cuts target work on antivirals and vaccines to prevent future...
On Tuesday, drug discoverer and biotech entrepreneur Alpha Lee told scientists at a chemistry meeting about a new molecule to combat the Zika virus. There are no treatments designed to stop the...
View ArticleFDA's Peter Marks resigns, in disagreement with Kennedy
Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research and one of the agency's highest-profile officials, has suddenly resigned amid a simmering disagreement with the Trump...
View ArticleHHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy;...
Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The Senate confirmed nominations this week for Johns Hopkins researcher Marty...
View ArticleVertex’s second-generation diabetes cell therapy fails early-stage study
Vertex Pharmaceuticals announced Friday afternoon that it won't move forward with its type 1 diabetes cell therapy that's delivered in a device meant to get rid of the need for immunosuppression ...
View ArticleExclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and...
SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time to advance new Parkinson's disease treatments. The London-based healthcare...
View ArticleBiomX’s phage therapy BX211 succeeds in Phase 2 diabetic bone infection study
BiomX’s antibacterial virus candidate has reduced the size of foot ulcers in patients with diabetic bone infection enrolled in a mid-stage trial. The finding could strengthen the company’s case for an...
View ArticleTranscend's neuroplastogen notches Phase 2 win to treat PTSD
Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 trial that could begin at the start of next year. The...
View ArticleAlphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025
Google’s bet on AI in drug discovery just got a lot bigger. Isomorphic Labs said Monday it raised $600 million from Thrive Capital, GV and Alphabet in its first external financing. The raise is the ...
View ArticleInspirna, which was preparing for a Phase 3 cancer trial, has folded
A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is shutting down, a blow to a company that was prepping for a pivotal ...
View ArticleLifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne...
Plus, news about Opthea, Apollomics, LaunXP and AstraZeneca: LifeMine reduces headcount: The Boston biotech went through a “company-wide restructuring,” according to employees’ LinkedIn posts. The...
View ArticleLilly's heart drug study shows potential for once-a-year dosing
Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing treatments in development from Novartis and Amgen, giving Lilly a way into an...
View Article